Sigrid Therapeutics has announced that the European Patent Office has granted the company patent titled “A porous silica material for use as a pharmaceutical or dietary active ingredient”.
The patent supports use of Sigrid’s mesoporous silica particles (MSP)-based device which consists of precisely engineered micron-sized silica particles with tailored porosity designed to act locally in the gut as a pharmaceutical and dietary active ingredient. Covering the EU, UK, Switzerland, Norway, Iceland and Turkey, the European patent follows similar grants in the US, Canada, Australia, Japan and Israel and significantly strengthens Sigrid’s IP portfolio.
“This European patent marks the start of a breakthrough year for Sigrid as we look to start our pivotal clinical trial SHINE in obese and overweight individuals with higher-than-normal blood sugar levels. We have secured manufacturing capacity and are attracting growing interest worldwide from opinion leaders representing both the medical and nutritional fields,” says Ghislaine Robert Nicoud, Material Researcher & IP Manager, Sigrid Therapeutics.